PHAT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PH

Mkt Cap

$559.4M

Volume

1.08M

Next Earnings

October 29th

Loading chart

PH

PHATPhathom Pharmaceuticals, Inc. Common Stock

PHAT

Pay with—

Available Balance0.00

PH

Mkt Cap

$606.8M

Volume

1.08M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Phathom Pharmaceuticals to Participate in Upcoming Investor ConferencesPhathom Pharmaceuticals announced that its management team will participate in two major investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. Both events will feature fireside chats and one-on-one meetings with investors. Live webcasts and 90-day archived recordings will be available on the company's investor relations website.GlobeNewswire Inc. · Sep 1, 2026

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingPhathom Pharmaceuticals announced its participation in Digestive Disease Week 2026, where it will present clinical and real-world data on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker for GERD treatment. The company reported Q1 2026 net revenues of $58.3 million, representing 104% year-over-year growth, with 1.35 million total VOQUEZNA prescriptions filled to date.GlobeNewswire Inc. · May 1, 2026

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightThe US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.GlobeNewswire Inc. · Apr 13, 2026

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.Benzinga · Jan 8, 2026

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded WarrantsPhathom Pharmaceuticals priced a $130 million underwritten public offering consisting of 6.875 million shares of common stock at $16.00 per share and 1.25 million pre-funded warrants at $15.999 per warrant. The offering is expected to close on January 9, 2026, with net proceeds intended for general corporate purposes including working capital, commercialization, and R&D expenses. Guggenheim Securities and Cantor are serving as joint bookrunning managers.GlobeNewswire Inc. · Jan 8, 2026

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific MeetingPhathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting, showcasing VOQUEZNA® (vonoprazan) as an approved treatment for Gastroesophageal Reflux Disease (GERD) through product theater presentations and exhibit booth interactions.GlobeNewswire Inc. · Oct 23, 2025

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025Phathom Pharmaceuticals will host a live webcast on October 30, 2025, at 8:00 am EDT to report its third quarter 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.GlobeNewswire Inc. · Oct 20, 2025

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D FilingPhathom Pharmaceuticals announced administrative changes to a Schedule 13D filing by Frazier Life Sciences, emphasizing that these changes do not represent a reduction in ownership position, but rather reflect reporting approach modifications.GlobeNewswire Inc. · Aug 20, 2025

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025Phathom Pharmaceuticals will host a live webcast on August 7, 2025, at 8:00 am EDT to report its Q2 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.GlobeNewswire Inc. · Jul 28, 2025

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of DirectorsPhathom Pharmaceuticals, a biopharmaceutical company, announced the appointment of Ted Schroeder, a seasoned biopharma leader, to its Board of Directors. Schroeder's deep operational and commercial expertise is expected to be an important asset as Phathom continues to unlock the full potential of its lead product, VOQUEZNA.GlobeNewswire Inc. · Apr 16, 2025

to start trading

PH

PHATPhathom Pharmaceuticals, Inc. Common Stock

PHAT

Pay with—

Available Balance0.00

Your PositionYou don't own any PHAT yet.

Related Tickers

Earnings